跳至主要内容
临床试验/NCT05529472
NCT05529472已完成不适用

KAIZEN: Safety and Effectiveness Evaluation of Peripheral Orbital Atherectomy

Abbott Medical Devices21 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2023年1月10日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
100
试验地点
21
主要终点
Percentage of Subjects With Acute Device Success

研究概览

简要总结

This is a prospective, single-arm, multi-center study designed to evaluate the safety and efficacy of the Orbital Atherectomy System (OAS) for the treatment of adult Japanese subjects with a de novo symptomatic calcified occlusive atherosclerotic lesion in the superficial femoral artery (SFA) and/or popliteal (POP) artery, which would be otherwise ineligible for endovascular therapy due to risk of complication. Study objective is to collect safety and effectiveness data to support potential commercialization of the peripheral OAS device in Japan.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Percentage of Subjects With Acute Device Success

时间窗: At the end of the procedure

The percentage of subjects with the following, post-procedure: 1. ≤50% residual stenosis post OAD + POBA \[Angiographic Core Lab assessed\] and, 2. No OAS-related severe angiographic complications defined as severe dissections (D-F), perforation, or distal emboli requiring additional treatment during the procedure \[CEC adjudicated\].

次要结局

  • Change in Lesion Stenosis(Baseline, Post OAD, Post POBA)
  • Acute Technical Success(At the end of the procedure)
  • Drug Coated Balloon (DCB) Device Success(Within 3 minutes of insertion of DCB)
  • Target Vessel Patency(Up to 6 months)
  • Rate of Severe Angiographic Complications(At the end of the procedure)
  • Change in Ankle Brachial Index (ABI)(Baseline (within 30 days of the clinical treatment), and Post Procedure (after the clinical trial treatment prior to discharge: post procedure ABI was collected on average 1.1 days post clinical trial treatment))
  • Acute Procedural Success(72 hours after index procedure)
  • Rate of Major Adverse Event (MAE)(30 days and 6 months)
  • Change of Rutherford Classification (ITT Population)(Baseline, 30 days and 6 months)
  • Change of Rutherford Classification (mITT Population)(Baseline, 30 days and 6 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (21)

Loading locations...

相似试验